HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published All Versions of this Article: ERC-09-0076v1 16/4/1283    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Hänscheid, H. Articles by Reiners, C. Search for Related Content PubMed PubMed Citation Articles by Hänscheid, H. Articles by Reiners, C.

Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Straße 6, D-97080 Würzburg, Germany
¹ Divisions of Endocrinology and Nuclear Medicine, Departments of Internal Medicine and Radiology, The Ohio State University, 446 McCampbell Hall, 1581 Dodd Drive Columbus, OH 43210-1296, USA

(Correspondence should be addressed to H Hänscheid; Email: haenscheid{at}nuklearmedizin.uni-wuerzburg.de)

A simple method is presented to estimate the radiation-absorbed dose to the blood after radioiodine administration from a single external measurement of the whole-body retention in patients suffering from differentiated thyroid cancer. The blood dose is calculated applying the formalism of the Medical International Radiation Dose Committee under the assumptions that whole-body activity decays exponentially and that 14% of the whole-body residence time can be attributed to the blood. Accuracy and applicability of the method were tested based on data from 29 assessments, 18 pre-therapeutic tracer studies, and 11 ablation therapies, with whole-body and blood-retention measurements over at least 4 days. The mean of the absolute deviations between estimates and actual blood doses was found to be 14%, if external whole-body counting was performed on day 1 or 2 after radioiodine administration. This simple formalism is: 1) applicable to pre-therapeutic dosimetry for remnant ablation or treatment of metastases in a blood dose-based treatment concept and 2) applicable to blood-dose estimates after radioiodine therapy to determine radiation exposure. When combined with a measurement of the whole body retention 1 or 2 days after radioiodine administration this single time-point method closely approximates the classic, yet much more labor intensive multi-day dosimetry that measures both blood and whole-body activities.

This article has been cited by other articles:

				M. Lassmann, C. Reiners, and M. Luster Dosimetry and thyroid cancer: the individual dosage of radioiodine Endocr. Relat. Cancer, September 1, 2010; 17(3): R161 - R172. [Abstract] [Full Text] [PDF]

				M. Lassmann, H. Hanscheid, D. Gassen, J. Biko, V. Meineke, C. Reiners, and H. Scherthan In Vivo Formation of {gamma}-H2AX and 53BP1 DNA Repair Foci in Blood Cells After Radioiodine Therapy of Differentiated Thyroid Cancer J. Nucl. Med., August 1, 2010; 51(8): 1318 - 1325. [Abstract] [Full Text] [PDF]